Product: Metronidazole Tablets IP / BP / USP
Brands: Cirogyl-400 (oral); Metro V-250 (vaginal)
Oral strengths: 200 mg, 250 mg, 400 mg, 500 mg
Vaginal product: Metronidazole BP 250 mg — separate route
Usage: Susceptible anaerobic bacterial and protozoal infections
Category: Antibiotic Drugs
Therapeutic category: Nitroimidazole antibacterial / antiprotozoal
SKU: Metronidazole Tablets
Categories: Pharmaceutical Exporter India, Pharmaceutical Formulations India, WHO GMP Certified Formulations
Metronidazole Tablets is listed in our pharmaceutical product portfolio for business-to-business enquiries. Product-specific formulation details, available strengths, dosage form, pack configuration and supply terms should be confirmed against the current product specification before ordering.
For distributor, wholesaler, hospital procurement and export enquiries, please request the applicable product specifications, batch documentation, shelf-life information, packaging options and regulatory documents. Availability and documentation depend on the product and destination market.
Manufacturer: Healthy Life Pharma Pvt. Ltd. (WHO-GMP certification subject to verification)
Exporter: Healthy Inc (Star Export House status subject to verification)
Metronidazole is a nitroimidazole antibacterial and antiprotozoal medicine used for susceptible anaerobic bacterial infections and certain protozoal infections. Oral formulations may be used for conditions including amoebiasis, giardiasis, trichomoniasis and selected anaerobic infections, subject to local approval and medical assessment.
The supplied range includes Metronidazole Tablets IP, BP and USP, and a distinct Metro V-250 vaginal tablet. Healthy Life Pharma Pvt. Ltd. is identified as manufacturer and Healthy Inc as exporter in the supplied material. Certification, export credentials and manufacturing claims require verification.
| Standard / product | Strength | Dosage form / details |
|---|---|---|
| Metronidazole IP | 200 mg, 400 mg | Uncoated and film-coated oral tablets |
| Metronidazole BP | 250 mg | Sugar-coated oral tablet; another BP 250 mg entry mentions titanium dioxide as excipient |
| Metronidazole BP — Cirogyl-400 | 400 mg | Film-coated oral tablet |
| Metronidazole BP | 500 mg | Oral tablet; supplied description mentions brilliant blue excipient |
| Metronidazole USP | 200 mg, 400 mg, 500 mg | Uncoated oral tablets |
| Metro V-250 — Metronidazole BP | 250 mg | Vaginal tablet, not for oral administration |
| CAS number (metronidazole) | 443-48-1 | |
| Therapeutic class | Nitroimidazole antibacterial / antiprotozoal | |
| SKU | Metronidazole Tablets | |
| Shelf life / packaging | To be confirmed against approved product stability data and registered pack | |
Important: Oral tablets and Metro V-250 vaginal tablets are different routes of administration and must have separate approved labeling, directions and product records.
Depending on the approved formulation, manufacturing controls may address blending, compression, tablet disintegration, coating, taste characteristics, moisture protection and pack compatibility. The supplied text refers to taste-masking film coating and light-resistant packaging; the specific processes and equipment used for these products are not independently established.
Oral and vaginal tablets require route-specific formulation, quality controls, labeling and packaging to prevent administration errors.
Quality testing should follow the relevant registered IP, BP or USP monograph and product-specific specifications, including identity, assay, dissolution or disintegration as appropriate, uniformity, related substances and stability. Fixed dissolution percentages, assay limits, impurity specifications and 36-month shelf life cannot be confirmed from the supplied composition statements alone.
Claims of WHO-GMP certification, certificates of analysis, and regulatory approvals should be checked against current documents before publication.
Metronidazole is activated within susceptible anaerobic organisms and certain protozoa, producing intermediates that damage microbial DNA. Uses of oral metronidazole vary by indication and country and can include anaerobic bacterial infections, amoebiasis, giardiasis, trichomoniasis and use as part of combination regimens for certain other conditions.
Metro V-250 vaginal tablets have a separate route and should only be used for indications supported by their own locally approved label. Metronidazole is not effective against viral infections and is not a general treatment for all skin conditions or rosacea; rosacea often involves distinct topical formulations.
Export partners may require product registration dossiers, validated specifications, stability data, approved artwork, certificates of analysis, and country-specific documentation. Availability of CTD/ACTD dossiers, COPP, FSC, GMP certificates and particular shipping terms must be confirmed with Healthy Life Pharma Pvt. Ltd. and Healthy Inc.
Q: Which strengths are listed?
A: Oral tablets: 200 mg, 250 mg, 400 mg and 500 mg across the specified IP, BP and USP variants. Metro V-250 is a separate 250 mg vaginal product.
Q: Can Metro V-250 be swallowed?
A: No. A vaginal tablet must not be taken orally; use only according to its approved instructions.
Q: Can I drink alcohol during treatment?
A: Product labels often advise avoiding alcohol during treatment and for a period afterward because of possible adverse reactions, although evidence for a consistent disulfiram-like reaction is mixed. Follow the specific local product label; US oral labeling advises avoidance during treatment and for at least three days after.
Q: Why does metronidazole cause a metallic taste?
A: Taste disturbance, nausea and abdominal discomfort are recognized adverse effects.
Dose, duration and frequency depend on the infection, patient factors, formulation, route and approved local prescribing information. A single dose schedule is not suitable for all metronidazole indications. Complete the prescribed course and do not share antibiotics. Oral and vaginal dosage forms are not interchangeable. Clinicians should consider liver impairment, interacting medicines and treatment of sexual partners where applicable.
Common effects: Nausea, abdominal discomfort, metallic taste and headache. Serious effects: Peripheral neuropathy, seizures or other neurological symptoms, severe allergic reactions and blood-count abnormalities may occur. Seek prompt medical assessment for numbness, coordination changes, seizures or severe rash.
Interactions: Important interactions include warfarin and disulfiram; review other medicines with a clinician. Pregnancy and breastfeeding: Decisions depend on the indication, trimester, route, dose and current clinical guidance; a blanket first-trimester prohibition is not appropriate. Alcohol: Follow locally approved precautions and product labeling.
Store according to the approved product label in the original packaging, protected from unsuitable heat, moisture and light. The supplied below-25°C storage instruction requires verification against each registered product label. Keep out of reach of children and keep oral and vaginal products clearly separated.